Evaluation of antitumor immunity and paraneoplastic neurological syndrome evoked by murine dendritic cells pulsed with HuD antigen.
HuD 抗原脉冲的鼠树突状细胞引起的抗肿瘤免疫和副肿瘤神经综合征的评估。
基本信息
- 批准号:12670576
- 负责人:
- 金额:$ 2.05万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2000
- 资助国家:日本
- 起止时间:2000 至 2001
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
There is a clinically significant correlation between the presence of an antibody against the paraneoplastic encephalomyelitis antigen HuD (HuD antigen) and limitation of tumor spread in patients with small cell lung cancer (SCLC). The dendritic cells pulsed with tumor specific antigen such as HuD antigen will potentate the cellular immunity against the tumors. The expression of HuD antigen was evaluated by Western blotting in the murine splenic dendritic cells infected with HuD antigen expressing adenovirus vector. However, the expression of HuD antigen was not detectable by western blotting in the cells infected with our HuD-expressing adenovirus vector even at 50 moi (multiplicity of infection). Next we evaluated the effects of granulysin, a tumorcidal molecule secreted by cytotoxic T cells (CTL) and natural killer (NK) cells in HuD antigen-expressing small cell lung cancer murine model cells (Colon 26/HuD) infected with granulysin expressing adenovirus vector. Adenovirus vector-mediated transfer of 9kDa granulysin increased DNA fragmentation in Colon 26/HuD cells 2.5-fold and suppressed 21% of the Colon 26/HuD proliferation on day 3 (p<0.05 for each value) after the transfer of granulysin, compared with the control adenovirus vector transfer. In contract, adenovirus vector-mediated transfer of 9kDa granulysin did not increase DNA fragmentation nor suppress the proliferation of Colon 26 parent cells. The sensitivity of HuD-expressing tumor cells to granulysin is likely to partially explain the susceptibility of SCLC to cell-mediated immunity. These results support that HuD antigen is still good candidate molecule for antitumor immunity against SCLC and propose to evaluate the anti-tumor effect of dendritic cells pulsed with recombinant HuD antigen.
抗副肿瘤性脑脊髓炎抗原HUD(HUD抗原)抗体的存在与小细胞肺癌(SCLC)患者肿瘤扩散受限之间存在显著的临床相关性。用肿瘤特异性抗原如HUD抗原冲击的树突状细胞将增强抗肿瘤的细胞免疫。用免疫印迹法检测表达HUD抗原的腺病毒载体感染小鼠脾树突状细胞后HUD抗原的表达。然而,在表达HUD的腺病毒载体感染的细胞中,即使在50MOI(感染的多样性)的情况下,Western blotting也没有检测到HUD抗原的表达。接下来,我们观察了细胞毒性T细胞(CTL)和自然杀伤细胞(NK)分泌的杀瘤分子颗粒溶素对表达HUD抗原的小细胞肺癌小鼠模型细胞(COLON 26/HUD)感染颗粒溶素的作用。与对照组相比,腺病毒载体介导的9 kDa颗粒溶素转染组在转染腺病毒后第3天,结肠26/HUD细胞的DNA片段化增加2.5倍,增殖抑制21%(p<;每个值0.05)。而腺病毒载体介导的9 kDa颗粒溶素转染组并没有增加DNA片段化,也没有抑制亲本细胞的增殖。表达HUD的肿瘤细胞对颗粒溶素的敏感性可能部分解释了小细胞肺癌对细胞免疫的敏感性。这些结果支持HUD抗原仍然是抗小细胞肺癌抗肿瘤免疫的良好候选分子,并建议评价重组HUD抗原冲击的树突状细胞的抗肿瘤效果。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nagaoka I et al.: "Synergistic actions of antibacterial neutrophil defensins and cathelicidins."Inflamm Res. 49. 73-9 (2000)
Nagaoka I 等人:“抗菌中性粒细胞防御素和抗菌素的协同作用。”Inflamm Res。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Sekiya M et al.: "Adenovirus vector-mediated transfer of 9kDa granulysin induces DNA fragmentation in HuD antigen-expressing small cell lung cancer murine model cells."Respirology. 7. 29-35 (2002)
Sekiya M 等人:“腺病毒载体介导的 9kDa 颗粒溶素转移在表达 HuD 抗原的小细胞肺癌小鼠模型细胞中诱导 DNA 片段化。”呼吸学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yoshioka Y, et al.: "Increased circulating CD16^+ CD14^<dim> monocytes in a patient with pulmonary alveolar proteinosis"Respirology. (in press). (2002)
Yoshioka Y 等人:“肺泡蛋白沉积症患者循环 CD16^ CD14^<dim> 单核细胞增加”呼吸学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yoshioka Y., et al.: "Increased circulating CD16^+ CDl4^<dim> monocytes in a patient with pulmonary alveolar proteinosis"Respirology. (in press). (2002)
Yoshioka Y.等人:“肺泡蛋白沉积症患者循环CD16^CD14^<dim>单核细胞增加”呼吸学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Nagaoka I, et al.: "Synergistic actions of antibacterial neutrophil defensins and cathelicidins"Inflamm Res.. 49. 73-79 (2000)
Nagaoka I 等:“抗菌中性粒细胞防御素和抗菌肽的协同作用”Inflamm Res.. 49. 73-79 (2000)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OHWADA Akihiko其他文献
OHWADA Akihiko的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Phase Ib/II study of safety and efficacy of EZH2 inhibitor, tazemetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer
EZH2 抑制剂、他泽美司他和 PD-1 阻断治疗晚期非小细胞肺癌的安全性和有效性的 Ib/II 期研究
- 批准号:
10481965 - 财政年份:2024
- 资助金额:
$ 2.05万 - 项目类别:
Analysis of Pathology of AXL-MBIP Fusion Gene in Non-Small Cell Lung Cancer and Search for Therapeutic Targets
非小细胞肺癌AXL-MBIP融合基因的病理分析及治疗靶点的寻找
- 批准号:
23K15212 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying and targeting a novel mechanism of chemotherapy-induced immunotherapeutic resistance in non-small cell lung cancer
识别和靶向非小细胞肺癌化疗引起的免疫治疗耐药的新机制
- 批准号:
10657188 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Integrated fragment-based phenotypic screening and chemoproteomics for identification of novel small cell lung cancer-specific targets
基于片段的表型筛选和化学蛋白质组学相结合,用于鉴定新型小细胞肺癌特异性靶标
- 批准号:
10577507 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Advanced machine learning to empower ultra-sensitive liquid biopsy in melanoma and non-small cell lung cancer
先进的机器学习使黑色素瘤和非小细胞肺癌的超灵敏液体活检成为可能
- 批准号:
10591304 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Developing a novel therapeutic strategy to overcome multidrug resistance in small-cell lung cancer by activating innate immunity
开发一种新的治疗策略,通过激活先天免疫来克服小细胞肺癌的多药耐药性
- 批准号:
23K07639 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancer
CARM1-NFIB 轴在小细胞肺癌中的作用机制和治疗靶向
- 批准号:
10657854 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
肿瘤衍生新表位的自身抗体作为生物标志物和免疫 PET 试剂用于小细胞肺癌的早期检测
- 批准号:
10715807 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
A biomarker-driven strategy to guide the use of radiotherapy in non-small cell lung cancer
指导非小细胞肺癌放疗使用的生物标志物驱动策略
- 批准号:
10518064 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Identifying strategies to therapeutically target the unique epigenetic landscape of small cell lung cancer
确定针对小细胞肺癌独特表观遗传景观的治疗策略
- 批准号:
490137 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Operating Grants














{{item.name}}会员




